Summary Eight anthracycline analogs that have been shown to modulate multidrug resistance (Friche et al., Biochem. Pharmacol., 39, 1721-1726 were tested for their inhibitory effect on the photolabelling of P-glycoprotein. We photoaffinity labelled P-glycoprotein in daunorubicin (DNR) 
Thus vincristine was more potent than any of the eight anthracyclines tested, despite its relatively low lipophilicity. Increasing the concentration of DNR, 40 iM resulted in 90, 99.5 and 99.5% inhibition of P-glycoprotein labelling by ['251I] iodomycin, respectively. In comparison with the other anthracycline analogs, N,N-dibenzyl-DNR and Ad-198 were also found to exert the greatest inhibition of [3H]azidopine labelling of P-glycoprotein (about 90% at 100-fold molar excess). The solvents Cremophor EL and Tween 80 (30 jig ml-'; 0.003% v/v), which are modulators of multidrug resistance in EHR2/DNR + cells, also inhibited ['25I ]iodomycin labelling > 90%. We showed earlier that there is a correlation between the lipid solubility within the anthracycline group of MDR-associated drugs and their ability to enhance DNR accumulation in EHR2/DNR + cells but a corresponding correlation to lipophilicity when it comes to the inhibitory effect on the specific photolabelling of Pgp ligand binding sites could not be demonstrated. Neither could a correlation between the modulating effect of the analogs on DNR accumulation and inhibition on the labelling of Pgp be demonstrated. With increasing lipophilicity of the analogs it seems that the chemical structure plays a lesser role, and the degree of lipophilicity becomes a more important feature.
Anthracyclines are among the most valuable cytostatic agents in clinical use. Their usefulness is, however, limited by the occurrence of tumour cells with the multidrug resistance (MDR) phenotype (Beck, 1987; Bliek & Borst, 1989; Endicott & Ling, 1989; Kaye & Merry, 1985; Moscow & Cowan, 1988) . MDR cells have an enhanced amount of a 150-170 kDa plasma membrane glycoprotein, P-glycoprotein (Pgp) (Kartner et al., 1983 and 1985; Cornwell et al., 1986; Bradley et al., 1988; Beck, 1991a; Roninson, 1991) , that may function as a low-specificity transport protein to facilitate the outward transport of cytotoxic agents including the anthracyclines. Thus, increased drug efflux and therefore decreased accumulation is seen in MDR cells not only to the drug for which resistance is developed but also to a wide spectrum of chemically unrelated cytostatics (Bradley et al., 1988; Fojo et al., 1985) . A variety of compounds have been shown to bind to Pgp: Vinca alkaloids, progesterone, azidopine, verapamil analogs, prazosin, iodomycin, and Nazido-benzoyldaunomycin (recently reviewed by Beck & Qian, 1992) . We have reported earlier, that several anthracycline analogs in vitro were able to modulate DNRresistance in Ehrlich ascites tumour cells by enhancing the drug accumulation (Friche et al., 1990a) . The aim of this study was to examine these analogs for their ability to compete for ligand binding to Pgp and thus service as inhibitors for the outward drug transport system in MDR cells. Anthracycline inter-actions with Pgp were assessed using the specific photolabelling of the protein with [251I]iodomycin, a ['251 ]iodinated Bolton-Hunter derivative of DNR (Busche et al., 1989a) (Sehested et al., 1990) as well as in whole cells (Safa et al., 1987; Friche et al., 1990c) . Further, we have studied the inhibitory effects of AZP, vincristine, and detergents on the photoreaction of these compounds with Pgp. Material and methods Chemicals Duanorubicin (DNR); AdriamycinR (Doxorubicin/HCl, DOX); 4'-deoxy-4'-iododoxorubicin (DIDOX); and 4-demethoxy-DNR were kindly supplied from Farmitalia, Carlo Erba (Milan, Italy) . N,N-dibenzyl-DNR was a gift from Dr Nicholas Bachur, (Baltimore, MD) and Nbenzyladriamycin-14-valerate (AD 198) (Dan0, 1971 ) displaying both the MDR phenotype (Sehested et al., 1990 ) and as recently shown, decreased amount of topoisomerase II (Friche et al., 1991) . Resistance to DNR was developed and maintained in vivo in mice as previously described in detail (Dan0, 1971) . In vivo the subline is at least 16-fold resistant to DNR (Friche et al., 1987) and in vitro in a clonogenic assay about 80-fold resistant (Friche et al., 1990b) . No (Merck, Germany) with the solvent system ethyl acetate/diethyl ether (2:1, v/v, Rf 0.12), and extracted from the silica by ethanol (2 x 1 ml). The solvent was evaporated under a stream of nitrogen to a final volume of about 200 jAl. The radiochemical yields on the basis of Bolton-Hunter reagent were typically 50-60%.
Drug accumulation and lipophilicity
Drug accumulation experiments with EHR2 and EHR2/ DNR + cells and determination of drug lipophilicity by octanol/water partitioning were carried out as described previously (Friche et al., 1990 a,b,c Tables I and II) . The samples were incubated for 30 min at 37°C, before irradiation under 254 nm UV light for 20min. The cells were then transferred to Eppendrof tubes and centrifuged for 2 min at 10,000 rpm. Fifty jil of 1% NP 40 were added to dissolve the cell pellets and after 10min, the suspensions were centrifuged for 5 min at 15,000 rpm. The resulting supernatants were transferred to new tubes and 10 jAl of SDS (10%) and 10lA of bromphenolblue in 50% glycerol were added before analysis by SDS PAGE using 10% gels. Control experiments confirmed complete extraction of Pgp from the cells by this procedure. Following electro- 
Discussion
Overexpression of Pgp (Riordan & Ling, 1985) and inhibition of its function by several classes of membrane-active drugs (Beck, 1991b) are characteristic features of the MDR phenotype. Since various anthracycline analogs (Friche et al., 1990a) and VCR (Inaba & Nagashima, 1986) ['251] iodomycin in EHR2/DNR + relative to EHR2 (42 and 207 fmol 10-6 cells, respectively), in agreement with the data of Busche et al., (1989a) indicating that iodomycin itself is transported by the MDR efflux process. Zamora et al., 1988 and Pearce et al., 1989 have shown that some ideal structures have to be present to fulfill the demands for a good modulator: at least two planar aromatic rings, a basic nitrogen that would be positively charged at physiological pH and some lipophilicity. The tested anthracycline analogs fulfill all these demands and yet their effects as modulators are very varying. DNR had a significant effect in inhibiting photolabelling of Pgp by its N-acylated analog ['25I] (Friche et al., 1990b) . This is in agreement with the finding that DIDOX, which accumulated to the same degree in both DNR-resistant and DNRsensitive Ehrlich cells, did not increase DNR accumulation and thus does not appear to be a substrate for Pgp (Friche et al., 1990b; Arcamone, 1985) . Similar results were obtained in the labelling experiments with [3H]AZP. One explanation might be that the nitrogen atom in DIDOX due to the close position to iodide is not charged at neutral pH (pKa = 6.4, Barbieri et al. (1987) ) and thus does not fulfill the requirements of the ideal modulator.
The ability of the various anthracycline analogs to increase DNR accumulation in EHR2/DNR + cells correlated well with their degree of lipid solubility (Friche et al., 1990a) Hofsli & Nissen-Meyer (1990) , Wadler & Yang (1991) , and Beck & Qian (1992) . Thus aclacinomycin A, and N, all (Busche et al., 1989b ) and 1 jaM (Safa et al., 1987) , respectively. In contrast to the results with AZP, VCR is found to be a surprisingly good inhibitor of iodomycin labelling of Pgp despite having a very low oil:water partition coefficient (1.98), which is in agreement with data from Beck & Qian (1992) (Yoshimura et al., 1989; Safa et al., 1990; Greenberger et al., 1991) , that Pgp has two photoaffinity drug binding sites, one in each half of the protein (Greenberger et al. 1991) , and that AZP noncompetitively inhibits the binding of vinblastine and cyclosporin A to Pgp (Tamai & Safa, 1991 (Yang et al., 1989; Fleming et al., 1992) as also reported here. Such results may reflect the possibility that these experiments were not always done under optimal conditions. However, given these caveats, we find that the conditions we chose allowed us to determine the relative ability of a particular class of compounds (in this case the anthracyclines) to compete with these radioactive labelled compounds. We believe that these probes can be used as first screening tools especially for a single class of drugs to obtain a preliminary indication as to whether the drugs might be substrates for Pgp.
